Publication Name	World Journal of Clinical Cases
Manuscript ID	52529
Country	Italy

Received	2019-12-05 07:49
Peer-Review Started	2019-12-03 12:21
To Make the First Decision
Return for Revision	2019-12-23 09:32
Revised	2020-01-09 15:59
Second Decision	2020-01-11 06:29
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-01-14 19:02
Articles in Press	2020-01-14 19:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-01-18 05:16
Publish the Manuscript Online	2020-02-06 02:37

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Michela Palleschi, Roberta Maltoni, Eleonora Barzotti, Elisabetta Melegari, Annalisa Curcio, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta and Andrea Rocca
Funding Agency and Grant Number
Corresponding Author	Michela Palleschi, MD, Doctor, Doctor, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola 47014, Italy. michela.palleschi@irst.emr.it
Key Words	Hormone receptor-positive advanced breast cancer; Endocrine therapy; Cyclin-dependent kinase 4/6 inhibitor; Pathological complete response; ;
Core Tip	The rate of pathological complete response (pCR) after endocrine therapy (ET) in hormone receptor-positive breast cancer is low, limiting the value of pCR as a surrogate endpoint for the effectiveness of this treatment. Moreover, radical resection of locoregional recurrence is difficult to achieve when the tumor invades critical structures, e.g. blood vessels. Several studies have evaluated whether ET could also be used as a research platform for testing novel drugs in patients with ER-positive disease.
Publish Date	2020-02-06 02:37
Citation	Palleschi M, Maltoni R, Barzotti E, Melegari E, Curcio A, Cecconetto L, Sarti S, Manunta S, Rocca A. Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. World J Clin Cases 2020; 8(3): 517-521
URL	https://www.wjgnet.com/2307-8960/full/v8/i3/517.htm
DOI	https://dx.doi.org/10.12998/wjcc.v8.i3.517

Full Article (PDF)	WJCC-8-517.pdf
Full Article (Word)	WJCC-8-517.docx
Manuscript File	52529-Review.doc
Answering Reviewers	52529-Answering reviewers.pdf
Audio Core Tip	52529-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	52529-Conflict-of-interest statement.pdf
Copyright License Agreement	52529-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	52529-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	52529-Language certificate.pdf
Peer-review Report	52529-Peer-review(s).pdf
Scientific Misconduct Check	52529-Scientific misconduct check.pdf
Scientific Editor Work List	52529-Scientific editor work list.pdf
CrossCheck Report	52529-CrossCheck report.pdf